Clinical outcomes and management of inflammatory bowel disease in the older patient

Christina Y Ha; Seymour Katz

doi:10.1007/s11894-012-0310-4

Clinical outcomes and management of inflammatory bowel disease in the older patient

Curr Gastroenterol Rep. 2013 Feb;15(2):310. doi: 10.1007/s11894-012-0310-4.

Authors

Christina Y Ha¹, Seymour Katz

Affiliation

¹ Meyerhoff Inflammatory Bowel Disease Center, Division of Gastroenterology and Hepatology, 1830 East Monument Street, Suite 430, Baltimore, MD, 21287, USA. [email protected]

PMID: 23307425
DOI: 10.1007/s11894-012-0310-4

Abstract

The management of inflammatory bowel disease in the older patient extends beyond the gastrointestinal tract. Pre-existing comorbidities, polypharmacy, functional status and physical reserve can impact disease course, response to therapy and quality of life. Current therapeutic endpoints may not be as immediately applicable to the older IBD patient at higher risk for adverse outcomes. This review focuses on the latest studies addressing the natural history, clinical course and therapeutic outcomes among the older IBD cohort.

Publication types

Review

MeSH terms

Adrenal Cortex Hormones / adverse effects*
Adrenal Cortex Hormones / therapeutic use
Aged
Aged, 80 and over
Anti-Inflammatory Agents, Non-Steroidal / adverse effects*
Anti-Inflammatory Agents, Non-Steroidal / therapeutic use
Colorectal Neoplasms / epidemiology*
Comorbidity
Drug Interactions
Humans
Immunosuppressive Agents / adverse effects
Inflammatory Bowel Diseases / diagnosis*
Inflammatory Bowel Diseases / drug therapy*
Inflammatory Bowel Diseases / epidemiology
Polypharmacy
Skin Neoplasms / epidemiology*
Tumor Necrosis Factor-alpha / antagonists & inhibitors

Substances

Adrenal Cortex Hormones
Anti-Inflammatory Agents, Non-Steroidal
Immunosuppressive Agents
Tumor Necrosis Factor-alpha